Hydromorphone for acute and chronic pain

Cochrane Database of Systematic Reviews

Volumn 2002, Issue 1, 2002, Pages

  Quigley, Columba ^a   Hobson, Anna ^a  

^a CHURCHILL HOSPITAL   (United Kingdom)

Author keywords

[No Author keywords available]

Indexed keywords

ALPHAPRODINE; BUPIVACAINE; COCODAMOL; DIAMORPHINE; DIPYRONE; EPINEPHRINE; FENTANYL; HYDROMORPHONE; INDOMETACIN; LORAZEPAM; MORPHINE; MORPHINE SULFATE; NALBUPHINE; NARCOTIC ANALGESIC AGENT; OXYCODONE; PETHIDINE; PLACEBO; SUFENTANIL;

BILIARY TRACT PAIN; CANCER PAIN; CHRONIC PAIN; COMBINATION DRUG THERAPY; CONTINUOUS INFUSION; DIARRHEA; DIPLOPIA; DIZZINESS; DOSE RESPONSE; DROWSINESS; DRUG DOSAGE FORM COMPARISON; DRUG DOSE COMPARISON; DRUG EFFICACY; DRUG FORMULATION; DRUG MEGADOSE; DRUG WITHDRAWAL; HUMAN; INTRACAUDAL DRUG ADMINISTRATION; KIDNEY COLIC; LABOR PAIN; LOW DRUG DOSE; MONOTHERAPY; MUCOSAL DRUG ADMINISTRATION; NAUSEA; PAIN; PATIENT CONTROLLED ANALGESIA; PATIENT PREFERENCE; POSTOPERATIVE PAIN; PRIORITY JOURNAL; PRURITUS; REVIEW; SEDATION; SIDE EFFECT; SINGLE DRUG DOSE; SOMNOLENCE; SYSTEMATIC REVIEW; UNSPECIFIED SIDE EFFECT; URINARY HESITANCY; VERTIGO; ACUTE DISEASE; CHRONIC DISEASE; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; RANDOMIZED CONTROLLED TRIAL;

ACUTE DISEASE; ANALGESICS, OPIOID; CHRONIC DISEASE; HUMANS; HYDROMORPHONE; PAIN; RANDOMIZED CONTROLLED TRIALS;

EID: 0036357004     PISSN: None     EISSN: 1469493X     Source Type: Journal    
DOI: 10.1002/14651858.CD003447     Document Type: Review

References (80)

1. Bruera E, Brenneis C, Michaud M, MacMillan K, Hanson J, MacDonald RN. Patient-controlled subcutaneous infusion for the treatment of cancer pain. J National Cancer Institute 1988;80:1152-4.
2. Bruera E, Sloan P, Mount B, Scott J, Suarez-Almazor M. A randomized, double-blind, double-dummy, crossover trial comparing the safety and efficacy of oral sustained-release hydromorphone with immediate-release hydromorphone in patients with cancer pain. Journal of Clinical Oncology 1996;14:1713-7.
3. Chang AK, Bijur PE, Meyer RH, et al.Safety and Efficacy of Hydromorphone as an Analgesic Alternative to Morphine in Acute Pain: A Randomized Clinical Trial. Annals of Emergency Medicine 2006;48:164-72.
4. Chaplan SR, Duncan SR, Brodsky JB, Brose WG. Morphine and hydromorphone epidural analgesia. Anesthesiology 1992;77:1090-4.
5. Chestnut DH, Choi WW, Isbell TJ. Epidural hydromorphone for postcesarean analgesia. Obstetrics and Gynecology 1986;68:65-9.
6. Coda BA, O'Sullivan B, Donaldson G, Bohl S, Chapman CR, Shen DD. Comparative efficacy of patient-controlled administration of morphine, hydromorphone, or sufentanil for the treatment of oral mucositis pain following bone marrow transplantation. Pain 1997;72:333-46.
7. Collins JJ, Geake J, Grier HE, Houck CS, Thaler HT, Weinstein HJ, et al.Patient-controlled analgesia for mucositis pain in children: a three-period crossover study comparing morphine and hydromorphone. Journal of Pediatrics 1996;129:722-8.
8. Deutsch EV. Postoperative analgesia with hydromorphone and meperidine: a double-blind comparison. Anesthesia and Analgesia 1968;47(6):669-71.
9. Dougherty TB, Baysinger CL, Henenberger JC, Gooding DJ. Epidural hydromorphone with and without epinephrine for post-operative analgesia after cesarean delivery. Anesthesia and Analgesia 1989;68:318-22.
10. Drakeford MK, Pettine KA, Brookshire L, Ebert F. Spinal narcotics for postoperative analgesia in total joint arthroplasy. Journal of Bone and Joint Surgery 1991;73(3):424-8.
11. Flaherty SA, Faut-Callahan M, Paice JA, Glandon GL, Newman LM, Shott S. A comparison of analgesic efficacy, patient satisfaction, and cost of three spinal-epidural analgesic regimens in the laboring parturient. Journal of the American Association of Nurse Anesthetists 1997;65(4):384.
12. Gaeta RR, Macario A, Brodsky JB, Brock-Utne JG, Mark JBD. Pain outcomes after thoractomy: lumbar epidural hydromorphone versus intrapleural bupivicaine. Journal of Cardiothoracic and Vascular Anesthesia 1995;9(5):534-7.
13. Goldberg RI, Shuman FI. Oral hydromorphone in trauma. Current Therapeutic Research 1965;7(5):284-8.
14. Goodarzi M. Comparison of epidural morphine, hydromorphone and fentanyl for postoperative pain control in children undergoing orthopaedic surgery. Paediatric Anaesthesia 1999;9:419-22.
15. Grosset AB, Roberts MS, Woodson ME, et al.Comparative efficacy of oral extended-release hydromorphone and immediate-release hydromorphone in patients with persistent moderate to severe pain: two randomized controlled trials. Journal of Pain and Symptom Management 2005;29:584-94.
16. Hagen NA, Babul N. Comparative clinical efficacy and safety of a novel controlled-release oxycodone formulation and controlled-release hydromorphone in the treatment of cancer pain. Cancer 1997;79:1428-37.
17. Halpern SH, Arellano R, Preston R, Carstoniu J, O'Leary G, Roger S, Sandler A. Epidural morphine vs hydromorphone in post-caesarean section patients. Canadian Journal of Anaesthesia 1996;43(6):595-8.
18. Hanna C, Mazuzan JE, Abajian J. An evaluation of dihydromorphinone in treating postoperative pain. Anesthesia and Analgesia 1962;41(6):755-61.
19. Hays H, Hagen N, Thirlwell M, Dhaliwal H, Babul N, Harsanyi Z, Darke AC. Comparative clinical efficacy and safety of immediate release and controlled release hydromorphone for chronic severe cancer pain. Cancer 1994;74:1808-16.
20. Henderson SK, Matthew EB, Cohen H, Avram MJ. Epidural hydromorphone: a double-blind comparison with intramuscular hydromorphone for postcesarean section analgesia. Anesthesiology 1987;66(6):825-30.
21. Houde RW. Clinical analgesic studies of hydromorphone. In: Foley KM, Inturrisi CE editor(s). Advances in Pain Research and Therapy. Vol. 8, New York: Raven Press, 1986:129-35.
22. Houde RW. Clinical analgesic studies of hydromorphone. In: Foley KM, Inturrisi CE editor(s). Advances in pain research and therapy. Vol. 8, New York: Raven Press, 1986:129-35.
23. Jain AK, McMahon FG, Reder R, Smith G. A placebo-controlled study of an oral solution of 5 and 10mg of hydromorphone hydrochloride in post operative pain. Clinical Pharmacology and Therapeutics. 1989; Vol. 45:175.
24. Jasani NB, O'Connor RE, Bouzoukis JK. Comparison of hydromorphone and meperidine for ureteral colic. Academic Emergency Medicine 1994;1:539-43.
25. Kopp A, Wachauer D, Hoerauf KH, et al.Effect of pre-emptive hydromorphone administration on postoperative pain relief -a randomized controlled trial. Wiener Klinische Wochenschrift 2000;112/23:1002-6.
26. Lavoie J, Vischoff D, Villeneuve E. Comparison of caudally administered morphine vs hydromorphone in paediatric cardiac surgical patients. British Journal of Anaesthestics 1996;76 S1:35.
27. Lehmann KA, Paral F, Sabatowski R. Postoperative pain therapy with hydromorphone and metamizole. A prospective randomized study in intravenous patient-controlled analgesia (PCA) [Postoperative Schmerztherapie mit Hydromorphon and Metamizol. Eine prospektiv randomisierty Untersuchung im Rahmen der intravenosen patientenkintrolliertrn Analgesie (PCA)]. Anaesthesist 2001;50:750-6.
28. Liu S, Carpenter RL, Mulroy MF, Weissman RM, McGill TJ, Rupp SM, Allen HW. Intravenous versus epidural administration of hydromorphone. Anesthesiology 1995;82:682-8.
29. Mahler DL, Forrest WH. Relative analgesic potencies of morphine and hydromorphone in postoperative pain. Anesthesiology 1975;42(5):602-7.
30. Mahler DL, Forrest WH. Relative analgesic potencies of morphine and hydromorphone in postoperative pain. Anesthesiology 1975;42(5):602-7.
31. Miller MG, McCarthy N, O'Boyle CA, Kearney M. Continuous subcutaneous infusion of morphine vs. hydromorphone: a controlled trial. Journal of Pain and Symptom Management 1999;18:9-16.
32. Moriarty M, McDonald CJ, Miller AJ. A randomised crossover comparison of controlled release hydromorphone tablets with controlled release morphine tablets in patients with cancer pain. Journal of Clinical Research 1999;2:1-8.
33. Moulin DE, Kreeft JH, Murray-Parsons N, Bouquillon AI. Comparison of continuous subcutaneous and intravenous hydromorphone infusions for management of cancer pain. Lancet 1991;337:465-8.
34. Napp Laboratories. A comparative efficacy and tolerability study of Palladone capsules and MST Continus tablets in patients with cancer pain. Data on file.
35. Nasits BJ. Dental evaluation of hydromorphone (Dilaudid) for oral and maxillo-facial surgery. Texas Dental Journal 1969;87(5):4-6.
36. Parker EO, Brookshire GL, Bartel SJ, Menard RG, Culverhouse ED, Ault LC. Effects of epinephrine on epidural fentanyl, sufentanil and hydromorphone for postoperative pain. Anesthesiology 1985;63(3A):A235.
37. Parker RK, White PF. Epidural patient-controlled analgesia: an alternative to intravenous patient-controlled analgesia for pain relief after cesarean delivery. Anesthesia and Analgesia 1992a;75:245-51.
38. Parker RK, Sawaki Y, White PF. Epidural patient-controlled analgesia: influence of bupivicaine and hydromorphone basal infusion on pain control after cesarean delivery. Anesthesia and Analgesia 1992b;75:740-6.
39. Parker RK, Holtman B, White PF. Patient-controlled epidural analgesia: interactions between nalbuphine and hydromorphone. Anesthesia and Analgesia 1997;84:747-63.
40. Rapp SE, Egan KJ, Ross BK, Wild LM, Terman GW, Ching JM. A multidimensional comparison of morphine and hydromorphone patient-controlled analgesia. Anesthesia and Analgesia 1996;82:1043-8.
41. Searle NR, Roy M, Bergeron G, Perrault J, Roof J, Heermans C, et al.Hydromorphone patient-controlled analgesia (PCA) after coronary artery bypass surgery. Canadian Journal of Anaesthesia 1994;41(3):198-205.
42. Sharar SR, Bratton SL, Carrougher GJ, Edwards WT, Summer RN, Levy FH, et al.A comparison of oral transmucosal fentanyl citrate and oral hydromorphone for inpatient pediatric burn wound care analgesia. Journal of Burn Care and Rehabilitation 1998;19:516-21.
43. Swica L, Midgley J, Nunn R, Muir H, Shukla R, Smith B. Patient controlled epidural analgesia with hydromorphone versus single dose epidural morphine for post-caesarean analgesia. Canadian Journal of Anaesthesia 1998;45:A63.
44. Uden P, Starck CJ, Berger T. Comparison of indomethacin and dihydromorphinone in acute, biliary stone pain. Current Therapeutic Research 1984;36(6):1228-34.
45. Urquhart ML, Klapp K, White PF. Patient-controlled analgesia: a comparison of intravenous versus subcutaneous hydromorphone. Anesthesiology 1988;69(3):428-32.
46. Vanier MC, Labrecque G, Lepage-Savary D, Poulin E, Provencher L, Lamontagne C. Comparison of hydromorphone continuous subcutaneous infusion and basal rate subcutaneous infusion plus PCA in cancer pain: a pilot study. Pain 1993;53:27-32.
47. Wallenstein SL, Houde RW, Portenoy R, Lapin J, Rogers A, Foley KM. Clinical analgesic assay of repeated and single doses of heroin and hydromorphone. Pain 1990;41:5-13.
48. Wolanskyj AP, Schroeder G, Wilson PR, et al.A randomized, placebo-controlled study of outpatient premedication for bone marrow biopsy in adults with lymphoma. Clinical Lymphoma 2000;1(2):154-7.
49. Bruera E, Watanabe S, Fainsinger RL, et al.Custom-made capsules and suppositories of methadone for patients on high-dose opioids for cancer pain. Pain 1995;62(2):141-6.
50. Coyle N, Mauskop A, Maggard J, et al.Continuous subcutaneous infusions of opiates in cancer patients with pain. Oncology Nursing Forum 1986;13(4):53-7.
51. Dunbar PJ, Chapman CR, Gavrin JR. Clinical analgesic equivalence for morphine and hydromorphone with prolonged PCA. Pain 1996;68:265-70.
52. Inturrisi C, Portenoy R, Stillman M, et al.Hydromorphone bioavailability and pharmacokinetic-pharmacodynamic (pk-pd) relationships. Clinical Pharmacology and Therapeutics 1988;43(2):162.
53. Keeri-Szanto M. Anaesthesia time/dose curves IX: the use of hydromorphone in surgical anaesthesia and postoperative pain relief in comparison to morphine. Canadian Anaesthetists Society Journal 1976;23:587-95.
54. Keeri-Szanto M. Drugs or drums: what relieves postoperative pain. Pain 1979;6(2):217-30.
55. Kerr IG, Sone M, Deangelis C, et al.Continuous narcotic infusion with patient-controlled analgesia for chronic cancer pain in outpatients. Annals of Internal Medicine 1988;108(4):554-7.
56. Krehl L. Medical experiences with dilaudid. Munch Med Wochenschr 1926;73:596-7.
57. McRae AL, Sonne SC. Opioid equivalency: A review. Journal of Pharmacy Practice 1998;11(5):394-404.
58. Seevers MH, Pfeiffer CC. A study of the analgesia, subjective depression, and euphoria produced by morphine, heroine, dilaudid and codeine in the normal human subject. The Journal of Pharmacology and Experimental Therapeutics 1935;56(2):166-87.
59. Shulman MS, Wakerlin G, Yamaguchi L, et al.Experience with epidural hydromorphone for post-thoracotomy pain relief. Anesthesia and Analgesia 1987;66:1331-3.
60. Steinberg SK, Kornijenko M. The role of hydromorphone in the treatment of cancer pain. Canadian Pharmacy Journal 1988;121:182-6.
61. Walker DJ, Zacny JP. Subjective, psychomotor, and physiological effects of cumulative doses of opioid mu agonists in healthy volunteers. Journal of Pharmacology and Experimental Therapeutics 1999;289:1454-64.
62. Brose WG, Tanelian DL, Brodsky JB, et al.CSF and blood pharmacokinetics of hydromorphone and morphine following lumbar epidural administration. Pain 1991;45:11-5.
63. Chan WH, Lin CJ, Tsai SP, et al.Comparison of subcutaneous hydromorphone with intramuscular meperidine for immediate postoperative analgesia. Kao-hsiung i hsaeeh k'o hsaeeh tsa chih 1999;15(7):419-27.
64. Coombs DW, Saunders RL, Fratkin JD, et al.Continuous intrathecal hydromorphone and clonidine for intractable cancer pain. Journal of Neurosurgery 1986;64:890-4.
65. Welti RS, Moldenhauser CC, Hug CC Jr, et al.High dose hydromorphone (Dilaudid) for coronary artery bypass surgery. Anaesthesica and Analgesia 1984;63:55-9.
66. Ashby M, Martin P, Jackson K. Opioid substitution to reduce adverse effects in cancer pain management. The Medical Journal of Australia 1999;170:68-71.
67. Babul N, Darke AC. Hydromorphone and metabolite pharmacokinetics in children. Journal of Pain and Symptom Management 1995;10:335-7.
68. Bruera E, Pereira J, Watanabe S, Belzile M, Kuehn N, Hanson J. Opioid rotation in patients with cancer pain. A retrospective comparison of dose ratios between methadone, hydromorphone and morphine. Cancer 1996;78:852-7.
69. Chen ZR, Irvine RJ, Somogyi AA, Bochner F. Mu receptor binding of some commonly used opioids and their metabolites. Life Sciences 1991;48:2165-71.
70. Higgins JPT, Green S, editors. Assessment of study quality. Cochrane Handbook for Systematic Review of Interventions 4.2.6. In: The Cochrane Library [updated September 2006]; Issue 2, 2007. Chichester, UK: John Wiley & Sons, Ltd.
71. Jacox A, Carr D, Payne R. New clinical practice guidelines for the management of pain in patients with cancer. New England Journal of Medicine 1993;330:651-5.
72. Jadad AR, Moore RA, Carroll D, et al.Assessing the quality of reports of randomized clinical trials: is blinding necessary?. Controlled Clinical Trials 1996;17:1-12.
73. Lawlor P, Turner K, Hanson J, Bruera E. Dose ratio between morphine and hydromorphone in patients with cancer pain: a retrospective study. Pain 1997;72:79-85.
74. Manfredi PL, Borsook D, Chandler SW, Payne R. Intravenous methadone for cancer pain unrelieved by morphine and hydromorphone: clinical observations. Pain 1997;70:99-101.
75. MacDonald N, Der L, Allan S, Champion P. Opioid hyperexcitability: the application of alternate opioid therapy. Pain 1993;53:353-5.
76. Moore RA, Gavaghan D, Tramer MR, et al.Size is everything -large amounts of information are needed to overcome random effects in estimating direction and magnitude of treatment effects. Pain 1998;78:209-16.
77. Nathanson I, Daland E. Use of Dilaudid in treating patients with cancer. New England Journal of Medicine 1935;213:741-6.
78. Sjogren P, Jensen N, Jensen P. Disappearance of morphine-induced hyperalgesia after discontinuing or substituting morphine with other opioid agonists. Pain 1994;59:313-6.
79. World Health Organisation. Cancer Pain Relief. 2nd Edition. Geneva: WHO, 1986.
80. Quigley C. Hydromorphone for acute and chronic pain. Cochrane Database of Systematic Reviews 2002, Issue 1. [DOI: 10.1002/14651858.CD003447]